Company intelligence / Profile preview

Neurava

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Neurava's platform has completed a clinical study in adults demonstrating seizure detection and cardiorespiratory impairment monitoring, with positive usability and performance results; pivotal multicenter studies in both adult and pediatric patients are ongoing as of 2024, aiming for FDA 510(k) submission.

Therapeutic areas: Neurology
Modalities: DeviceArtificial intelligenceWearable technology
Industry: Physiological Monitoring

Partnerships

UCB (strategic investor, clinical and epilepsy expertise)Purdue University (academic IP/licensing)Leading epilepsy clinical institutions (multi-site studies)

Beyond the preview

Go deeper on Neurava.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurava.

Explore the full profile